Momenta Pharmaceuticals, Inc. (MNTA)

[biopearl]

Dew, the market place has changed alright! Is there a scenario where if MNTA wins the patent case finally in DC that the damages (ok, I am getting ahead of things a little) could reflect not only lost revenues based on the current market but the market before Ampha entry (plus a multiple for damages?). I remember the CEO saying a long time ago that assessment of damages would be fairly simple arithmetic based on lost revenue plus damages (this was before the CAFC fiasco). If so, MNTA could eventually own Amphastar. Is it more likely after all this that MNTA will (real world) just accept a royalty and be content with the precedent being set to protect them going forward or is there a real chance the damages could be based on pre infringement pricing? Thanks bp